Clinical Report: Real-World Assessment of Anti-CGRP Therapy in Egypt
Overview
This study evaluates the effectiveness and tolerability of anti-CGRP therapies among migraine patients in Egypt, revealing a 68% favorable response rate. It also identifies significant barriers to access and adherence to treatment.
Background
Anti-CGRP therapies have been introduced in Egypt since 2019, yet their real-world effectiveness and tolerability remain underexplored. Understanding these factors is crucial for optimizing migraine management and improving patient outcomes. This study provides valuable insights into the challenges faced by patients in accessing and adhering to these therapies.
Data Highlights
Outcome
Results
Favorable response rate (≥50% improvement)
68% (54 patients)
Reduction in monthly migraine days
Clinically significant (p < 0.001)
Reduction in headache severity
Clinically significant (p < 0.001)
Reduction in HIT-6 and MIDAS scores
Clinically significant (p < 0.001)
Discontinuation rate
35 patients
Relapse rate after discontinuation
42.1%
Key Findings
68% of patients experienced a favorable response with ≥50% improvement.
Significant reductions in monthly migraine days, headache severity, and MIDAS/HIT-6 scores were observed.
Tolerability of anti-CGRP therapies was generally favorable.
35 patients discontinued treatment, primarily due to cost or lack of improvement.
42.1% of patients who discontinued treatment experienced a relapse.
Clinical Implications
Suggest specific strategies for healthcare providers to improve access and adherence.
Conclusion
The findings underscore the effectiveness of anti-CGRP therapies in real-world settings while highlighting significant challenges in treatment access and adherence. Further studies are needed to explore these issues in greater depth.
